Search Results



Your search for all items matches 11965 pages

Showing 1 - 50


breast cancer

Final Overall Survival Results of TH3RESA Trial in Breast Cancer

The final overall survival results of the phase III TH3RESA trial indicate a 32% reduction in risk of death with ado-trastuzumab emtansine (Kadcyla) vs treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer. The findings were reported in The ...

palliative care
hematologic malignancies

Lack of Access to Transfusions Limits Hospice Use by Patients With Blood Cancer

A new survey finds that doctors would refer more patients with incurable blood cancers to hospice for end-of-life care if they could receive transfusions, which are generally not available because of hospice reimbursement policies. The findings, published by Odejide et al in Cancer, help explain...

breast cancer

ASCO and CAP Invite Comment on Focused Update to HER2 Testing Guideline in Breast Cancer

Draft recommendations as part of a focused update to the ASCO/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017. For patients with invasive breast...

In Remembrance of H. Jean Khoury, MD, FACP

Winship Cancer Institute of Emory University is mourning the loss of an esteemed colleague: H. Jean Khoury, MD, FACP, died on Monday, May 22, after a year spent battling cancer. His many colleagues and friends remember him as an outstanding physician, researcher, and educator, and a respected and...

colorectal cancer

Non–V600 BRAF Mutations in Metastatic Colorectal Cancer

As reported by Jones et al in the Journal of Clinical Oncology, BRAF mutations occurring outside of codon 600 are found in a small proportion of cases of metastatic colorectal cancer and are associated with improved clinical outcome. Study Details The retrospective cohort study involved 9,643...

breast cancer

Tai Chi Chih vs Cognitive Behavioral Therapy for Insomnia in Breast Cancer Survivors

In a study reported in the Journal of Clinical Oncology by Irwin et al, Tai Chi Chih, a form of movement meditation, was noninferior to insomnia-specific cognitive behavioral therapy in improving insomnia in breast cancer survivors. Study Details In the study, 90 patients with insomnia from the...

Survivorship
Lung Cancer

Precision Medicine and My Own Activism Are Keeping Me Alive

In 2009, I was living my dream. My work as a business development manager for a technology company was thriving; I had a satisfying social life; I was active in sports, especially hiking and biking; and I was involved in social justice causes as a volunteer at San Quentin State Prison, helping...

Former Vice President Joe Biden and Congressman Kevin Yoder Pledge Continued Support to Conquer Cancer

In a nearly hour-long address to more than 4,500 attendees at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) on April 3, former Vice President Joe Biden lambasted President Trump’s proposed $5.8 billion budget cut to the National Institutes of Health (NIH) and...

Legislation

Impact of Proposed Cuts to NIH Budget: More Than Just About Cancer

If enacted, the proposed budget reduction of $5.8 billion to the National Institutes of Health (NIH) will slow research, deprive patients afflicted with cancer of hope, and deliver a devastating blow to our science workforce and the Commonwealth of Pennsylvania. This proposed reduction directly...

Breast Cancer
Symptom Management

OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases

Bisphosphonates were first synthesized more than a century ago, with their initial usage restricted to a range of industrial processes until their potential clinical relevance was appreciated in the late 1960s.1 Then, following development for the treatment of osteoporosis and Paget’s disease of...

Breast Cancer
Symptom Management

Zoledronic Acid Every 12 Weeks Noninferior to Every 4 Weeks in Skeletal-Related Event Rate for Breast Cancer With Bone Metastases

In the phase III OPTIMIZE-2 trial reported in JAMA Oncology, Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that an every-12-week schedule of zoledronic acid was noninferior to an every-4-week schedule with regard to skeletal-related event...

Issues in Oncology

Weight Management and Physical Activity in Cancer Care: From Research to Real World

Is there enough evidence to support the incorporation of weight management and physical activity interventions into an oncology practice? And if so, what is the best way to do it? The answer to the first question was a resounding yes from oncologists, patient advocates, dietitians, public health...

Issues in Oncology

Tackling the Obesity and Cancer Epidemic

Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining...

Breast Cancer

New Immunotherapy Trial in Breast Cancer at Fox Chase Cancer Center

Patients with some types of breast cancer will have a new clinical trial option at Fox Chase Cancer Center. Medical oncologists Lori Goldstein, MD, and Elias Obeid, MD, MPH, are opening a phase II immunotherapy clinical trial for newly diagnosed, locally recurrent, or metastatic HER2-overexpressing ...

Lung Cancer

Osimertinib in Metastatic EGFR T790M–Mutant NSCLC After EGFR Inhibitor Therapy

On March 30, 2017, osimertinib (Tagrisso) was granted regular approval for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M–mutant non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration (FDA)-approved test, who have progressed...

Statement From ASH President on Cancer Drug Parity Act

In response to the introduction of the Cancer Drug Parity Act (H.R. 1409) by Representatives Leonard Lance (R–NJ) and Brian Higgins (D–NY), American Society of Hematology (ASH) President Kenneth C. Anderson, MD, of the Dana-Farber Cancer Institute, issued the following statement: “Oral and...

James Allison, PhD, Named One of TIME ’s 100 Most Influential People in 2017

The University of Texas MD Anderson Cancer Center Chair of Immunology, James Allison, PhD—whose pivotal insight to attack cancer by treating the immune system instead of the tumor revived cancer immunotherapy—has been named to the 2017 TIME 100 Most Influential People. His approach launched a...

Breast Cancer
Issues in Oncology

Unique Challenges Facing Young Women With Breast Cancer

According to the American Cancer Society, over 252,700 new cases of invasive breast cancer will be diagnosed in 2017, and about 40,610 women will die of their disease. Between 7% and 10% of those new cases will be diagnosed in women younger than age 40, accounting for more than 40% of all cancer...

Sir Richard Peto, FRS, to Receive McGuire Award at 2017 SABCS

Sir Richard Peto, FRS, will receive the William L. McGuire Memorial Lecture Award at the 2017 San Antonio Breast Cancer Symposium (SABCS), to be held December 5–9. The McGuire Award was established in 1992 to honor William L. McGuire, MD, who, along with Charles A. Coltman, MD, founded SABCS in...

Breast Cancer

Palbociclib Combined With Aromatase Inhibitor in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

On March 31, 2017, palbociclib (Ibrance) was granted regular approval for treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.1,2 Palbociclib received...

Six NY Scientists Win Pershing Square Sohn Prize for Young Investigators in Cancer Research

The Pershing Square Sohn Cancer Research Alliance announced the six winners of the 4th annual Pershing Square Sohn Prize for Young Investigators in Cancer Research, awarded annually to promising early-career, New York City–area scientists. Recipients receive $200,000 in funding per year for up...

AACR Honors Mina J. Bissell, PhD, FAACR, With Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) recognized Mina J. Bissell, PhD, FAACR, with the 14th AACR Award for Lifetime Achievement in Cancer Research during the 2017 AACR Annual Meeting in Washington, DC. The AACR Award for Lifetime Achievement in Cancer Research was established in 2004 ...

Clark Chen, MD, PhD, to Join University of Minnesota

The University of Minnesota Medical School has announced the addition of Clark Chen, MD, PhD, as the Lyle French Chair in Neurosurgery and the Head of the University of Minnesota Medical School Department of Neurosurgery. He will assume his new position in August 2017. Dr. Chen is a nationally...

Gynecologic Cancers

Niraparib in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On March 27, 2017, the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula) was approved for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.1,2...

Prostate Cancer

What Is Appropriate Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer?

As the subtleties of metastatic prostate cancer become increasingly recognized, treatment should evolve accordingly, said Jessica M. Clement, MD, Assistant Professor of Medicine at the University of Connecticut Health System and Neag Cancer Center, Farmington. Of particular interest to Dr. Clement ...

Issues in Oncology

Setting His Presidential Course on Making Precision Medicine a Reality for More Patients

Ensuring that all patients with cancer have access to the potential benefits of precision medicine regardless of where they are treated has been a primary goal of Bruce E. Johnson, MD, FASCO, since the concept was first introduced following completion of the Human Genome Project in 2003. Dr....

Pancreatic Cancer

ESTRO 2017: Study Suggests Role for Radiotherapy in Extending Survival in Patients With Early-Stage Pancreatic Cancer

Radiotherapy at a high enough dose may increase survival in early-stage pancreatic cancer, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference.1 Previous research has suggested that radiotherapy may be of little help in this setting. The...

ASCO Wants to Hear From Your Practice—Take Part in the 2017 ASCO Practice Census

Encourage your practice to participate in the 2017 ASCO Practice Census—the only annual survey of the entire U.S. oncology practice community that aims to capture and describe changes in cancer care and oncology practice over time. The data and insights obtained from the Practice Census are...

ASCO’s New Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce

The hematology/oncology workforce continues to struggle with adequate representation of racial and ethnic minorities. To promote the development of an oncology workforce that reflects the demographics of the population it serves, ASCO has introduced its Strategic Plan for Increasing Racial &...

Enhance Your Annual Meeting Experience With Attendee Resources

Next month, more than 30,000 oncology professionals will gather in -Chicago for the 2017 ASCO Annual Meeting. This year’s theme, “Making a Difference in Cancer Care WITH YOU,” speaks to driving advances in cancer care and treatment through teamwork among clinicians, researchers, educators, and...

health-care policy

ASCO and Other Oncology, Medical Societies Speak Out Against White House's Proposed Budget Cuts

On May 23, President Trump presented the White House’s fiscal year 2018 budget request, which proposes a $7.18 billion cut to the National Institutes of Health (NIH)—a budget decrease of 21%. In addition, it cuts the Center for Disease Control and Prevention’s chronic disease...

Multiple Myeloma

Smoldering and Relapsed or Refractory Multiple Myeloma

Here are several abstracts selected from the proceedings of the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in smoldering and relapsed and/or refractory multiple myeloma. For the full details of these study abstracts, visit...

Pancreatic Cancer

Hydroxychloroquine Boosts Antitumor Activity of Neoadjuvant Chemotherapy for Pancreatic Cancer

Adding hydroxychloroquine, an inhibitor of autophagy, to neoadjuvant chemotherapy for pancreatic cancer increases its efficacy and alters the tumor’s molecular profile in a way that may render the tumor more susceptible to immune checkpoint inhibitors, according to interim data from a phase II...

gastroesophageal cancer

FDA Grants Priority Review to sBLA for Pembrolizumab in Recurrent or Advanced Gastric or GEJ Adenocarcinoma

The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda) seeking approval for treatment of patients with recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have already...

Ronald P. DeMatteo, MD, FACS, Named Chair of the Department of Surgery at Penn Medicine

Ronald P. DeMatteo, MD, FACS, has been named Chair of the Department of Surgery in the Perelman School of Medicine at the University of Pennsylvania. He will assume his new post July 1, 2017, and will lead a department that includes 130 faculty across 11 divisions who provide advanced patient care ...

JNCCN 360, the Source for Tumor-Specific News and Treatment Updates, Available Now

Launched during the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™, JNCCN360.org is the latest resource from the Journal of the National Comprehensive Cancer Network (JNCCN). Currently available for breast...

breast cancer

Effect of Fixed Second Appointments on Breast Cancer Screening Attendance

In a UK study reported in The Lancet Oncology, Allgood et al found that provision of a second timed appointment for breast cancer screening improved screening rates among women who did not attend a first offered appointment. Study Details In the study, women who were invited for breast screening...

head and neck cancer

Complications From Thyroid Cancer Surgery More Common Than Once Thought

As thyroid cancer rates rise, more patients are having surgery to remove all or part of their thyroid. A new study by Papaleontiou et al in The Journal of Clinical Endocrinology & Metabolism suggests complications from these procedures are more common than previously believed. Overall, 6.5% of ...

solid tumors

AKT Inhibitor Activity in AKT1-Mutant Solid Tumors

As reported by Hyman et al in the Journal of Clinical Oncology, a basket study has shown activity of an investigational ATP-competitive pan-AKT kinase inhibitor (AZD5363) in solid tumors with AKT1 E17K mutation. Study Details In the study, 52 patients with advanced estrogen...

breast cancer

Final Overall Survival Results of EMILIA Trial in Breast Cancer

As reported in The Lancet Oncology by Diéras et al, the final overall survival results of the phase III EMILIA trial show improved outcome with ado-trastuzumab emtansine (Kadcyla) vs capecitabine plus lapatinib (Tykerb) in previously treated HER2-positive advanced breast cancer. Approval of...

Survivorship
Colorectal Cancer

Expert Point of View: Patrick S. Sullivan, MD

”This was a great study and novel, asking what longer-term survivors with colon cancer are dying from—the toxicity of our treatment or population-risk illnesses?” commented session co-moderator, Patrick S. Sullivan, MD, Assistant Professor of Surgery and Chief Quality Officer, Division of Surgical ...

Survivorship
Colorectal Cancer

Common Causes of Death Predominate Among Long-Term Colorectal Cancer Survivors

Patients with colorectal cancer who survive at least 5 years are increasingly likely to die from causes that are common in the general population, highlighting the importance of screening and lifestyle modification, suggested a large cohort study conducted in California.1 The analysis of more than...

New ASCO Answers Fact Sheets for Your Patients

The ASCO Answers chemobrain fact sheet helps patients understand and manage the cognitive side effects of chemotherapy. Patients will learn about the causes, symptoms, management, and treatment of “chemobrain.” The ASCO Answers diarrhea fact sheet helps patients understand the causes and risks of...

Two Faculty Members From Johns Hopkins Elected to National Academy of Sciences

Johns Hopkins University faculty members Stephen B. Baylin, MD, and Robert F. Siliciano, MD, PhD, have been elected to the National Academy of Sciences in recognition of their “distinguished and continuing achievements in original research.” They are among 84 new members and 21 foreign associates ...

4 Reasons to Use Social Media at the ASCO Annual Meeting

Join the discussion: Use #ASCO17 on Twitter to follow and participate in the Annual Meeting conversation in real time. During this past year’s Annual Meeting, more than 16,000 health-care professionals, researchers, news outlets, patients, advocates, and other participants sent nearly 70,000...

Skin Cancer

New Immunotherapy Combinations Gain Ground in Advanced Melanoma, but Results Preliminary

Attention is focused among the cancer community on identifying the optimal immunotherapy combinations, with more than 800 ongoing trials of combination therapy. Two studies presented at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) reported promising preliminary...

ASCO Issues Recommendations for Reducing Cancer Disparities Among Sexual and Gender Minority Populations

ASCO has issued recommendations addressing the needs of sexual and gender minority populations as they relate to cancer.  The recommendations, published in a policy statement in the Journal of Clinical Oncology,1 are designed to focus attention on the challenges facing the sexual and gender...

Leukemia

Expert Point of View: David L. Porter, MD & Jonathan S. Serody, MD

In a separate interview with The ASCO Post, David L. Porter, MD, Director of Blood and Marrow Transplantation and the Jodi Fisher Horowitz Professor in Leukemia Care Excellence at the University of Pennsylvania, Philadelphia, said: “It is encouraging that many patients with acute lymphoblastic...

Leukemia

CAR T Cells in Relapsed B-Cell Acute Lymphoblastic Leukemia

Updated results in 51 adults with relapsed B-cell acute lymphoblastic leukemia (ALL) treated with chimeric antigen receptor (CAR) T cells at Memorial Sloan Kettering Cancer Center in New York showed high complete response rates regardless of pre–CAR T disease burden.1 That said, pretreatment...

Rafal Dziadziuszko, MD, PhD, Receives 2017 Heine H. Hansen Award

The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) awarded the 2017 Heine H. Hansen Award to Rafal Dziadziuszko, MD, PhD, at the European Lung Cancer Conference (ELCC) 2017, which was held May 5–8 in Geneva, Switzerland. The...

Advertisement



Advertisement


Advertisement

click me